Sciences, Inc. (NASDAQ: MELA), developer of MelaFind®,
an FDA approved optical diagnostic device that assists dermatologists in
melanoma diagnosis, today announced the appointment of veteran medical
device investment banker Samuel E. Navarro to the Board of Directors.
Mr. Navarro's appointment brings MELA's Board to eight members.
Mr. Navarro brings a wealth of knowledge and industry expertise in
finance, investment banking, mergers and acquisitions, equity research
and investment management experience in the medical device industry. Mr.
Navarro is currently Managing Partner at Gravitas Healthcare, LLC.
Before Gravitas, Mr. Navarro was Managing Director of Cowen & Co. in New
York City and head of their Medical Technology Investment Banking
initiatives, leading a team of senior people, and was responsible for
building the franchise across all product categories, including
M&A/Advisory and financing services and products. Before Cowen & Co.,
Mr. Navarro spent over four years at The Galleon Group running the
Galleon Healthcare Fund as a Senior Portfolio Manager. He was
responsible for all healthcare investments across all sectors, including
pharmaceuticals / biopharmaceutical industries, medical technology and
hospital supplies, and all areas of healthcare services. Prior to
Galleon, Mr. Navarro was Global Head of Healthcare Investment Banking at
Mr. Navarro has also served or serves on the boards of Arstasis,
MicroTherapeutics, Jomed, Photomedex and Pixelux Entertainment. Mr.
Navarro received an MBA in Finance from The Wharton School at the
University of Pennsylvania, a Master of Science in Engineering from
Stanford University and a Bachelor of Science in Engineering from The
University of Texas at Austin.
Mr. Navarro commented, "I am excited to contribute to the MELA Sciences
Board as they execute their U.S. and European commercialization strategy
for MelaFind and develop plans for other global markets. I also look
forward to working with the company to evaluate and develop other
potential applications for their optical diagnostic technology."
Rose Crane, CEO of MELA Sciences said, "Sam brings a tremendous breadth
of experience, expertise and relationships across the medical device and
healthcare industry and huge enthusiasm regarding MELA Sciences and our
potential. We look forward to the vital insight and guidance Sam will
provide as we move forward."
Please follow us:
Sciences or MelaFind
About MELA Sciences, Inc. www.melasciences.com
MELA Sciences is a medical device company developing dermatology
diagnostics utilizing state-of-the-art optical imaging. The flagship
product is MelaFind®, an FDA, PMA and CE Mark approved,
non-invasive diagnostic tool to aid dermatologists in melanoma
evaluation and diagnosis. MelaFind® uses a variety of visible
to near-infrared light waves to evaluate skin lesions from the surface
to 2.5 mm beneath the skin. It provides images and data on the relative
disorganization of a lesion's cell structure that provides substantial
additional perspective to aid melanoma diagnosis. MELA is also exploring
new potential uses for its core imaging technology and algorithms.
This press release includes "forward-looking statements" within the
meaning of the Securities Litigation Reform Act of 1995. These
statements include but are not limited to our plans, objectives,
expectations and intentions and may contain words such as "seeks," "look
forward," and "there seems" that suggest future events or trends. These
statements are based on our current expectations and are inherently
subject to significant uncertainties and changes in circumstances.
Actual results may differ materially from our expectations due to
financial, economic, business, competitive, market, regulatory and
political factors or conditions affecting the company and the medical
device industry in general, as well as more specific risks and
uncertainties set forth in the company's SEC reports on Forms 10-Q and
10-K. Given such uncertainties, any or all of these forward-looking
statements may prove to be incorrect or unreliable. MELA Sciences
assumes no duty to update its forward-looking statements and urges
investors to carefully review its SEC disclosures available at www.sec.gov
[ Back To NFVZone's Homepage ]